Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989.
Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989.
复制标题
健康儿童和青少年的水痘疫苗 (VARIVAX)：1987 年至 1989 年临床试验结果。
作者：
C. J. White;B. Kuter;C. S. Hildebrand;K. L. Isganitis;H. Matthews;W. J. Miller;P. Provost;Ronald W. Ellis;Robert J. Gerety;Gary B. Calandra
共有3303名年龄在12个月至17岁之间的健康儿童和青少年接种了5个生产批次的水痘减毒活疫苗（VARIVAX），每剂含1000至1625个空斑形成单位。疫苗一般耐受性良好。96%（2381/2475）的疫苗接种者通过糖蛋白酶联免疫吸附试验测定产生抗体对疫苗接种作出反应; 99%（569/576）的受试者在疫苗接种后1年保持抗体。接种者家庭暴露后水痘的发病率约为12%;历史上家庭接触导致87%的感染。几乎所有在接种疫苗后患水痘的接种者都是临床上改变的疾病。
A total of 3303 healthy children and adolescents, aged 12 months to 17 years, were vaccinated with one of five production lots of a live attenuated varicella vaccine (VARIVAX) containing 1000 to 1625 plaque-forming units per dose. The vaccine was generally well tolerated. Ninety-six percent (2381/2475) of vaccinees responded to vaccination by producing antibody as measured by a glycoprotein-based enzyme-linked immunosorbent assay; 99% (569/576) of those tested maintained antibody at 1 year following vaccination. The incidence of varicella following household exposure in vaccinees was approximately 12%; household contact historically results in 87% infection. Nearly all of the vaccinees who had varicella after vaccination had a clinically modified disease.